Results 21 to 30 of about 30,900 (164)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib

Indian Journal of Medical and Paediatric Oncology, 2011
The concomitant occurrence of pregnancy and chronic myelogenous leukemia is uncommon. We describe the successful management of a 24-year-old woman in the first trimester of her pregnancy with chronic myelogenous leukemia (CML) in the chronic phase, who ...
Jovita Martin, Anita Ramesh, Lalitha Devadasan, Palaniappan, Jude J Martin   +4 more
doaj   +1 more source

Rare Infectious Diseases: Detection and Clinical Implications

iLABMED, EarlyView.
Rare infectious diseases are infections that are uncommon, have a low incidence, and are caused by newly emerging pathogens, cross‐species or ectopic infections, or host immunodeficiencies. The detection and diagnosis of rare infections is one of the main reasons for misdiagnosis and missed diagnosis.
Xin Qian, Yuxin Zhang, Yilin Ye, Qiange Lin, Junyou Lin, Xinrong Lu, Li Chen, Guiqin Sun   +7 more
wiley   +1 more source

Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish

Haematologica, 2012
Background Chromosomal translocations resulting in alternative fusions of the human TEL (ETV6) and JAK2 genes have been observed in cases of acute lymphoblastic leukemia and chronic myelogenous leukemia, but a full understanding of their role in disease ...
Sara M. N. Onnebo, Parisa Rasighaemi, Janani Kumar, Clifford Liongue, Alister C. Ward   +4 more
doaj   +1 more source

Polypept(o)ide‐Based Core–Shell Bottlebrush Polymers: A Versatile Platform for Drug Encapsulation

Macromolecular Bioscience, EarlyView.
This study developed polypept(o)ide‐based core–shell brushes (CSBs) with tunable sizes (Rh: 17–70 nm) for hydrophobic drug delivery. CSBs achieved 10% dasatinib loading through π–π interactions, enabling sustained release over 72 h. Notably, CSB‐dasatinib complexes showed comparable cell viability reduction to the free drug in U‐87 MG cells ...
Bonan Zhao, Jingyuan Wei, Rüdiger Berger, Lin Jian, Kaloian Koynov, Heyang Zhang, Matthias Barz   +6 more
wiley   +1 more source

Bilineage T-lymphoblastic/myeloid extramedullary blast crisis in chronic myelogenous leukemia

Indian Journal of Pathology and Microbiology, 2016
The blast crisis of chronic myelogenous leukemia (CML) can be hematological or extramedullary. About 25% of these cases fulfill the criteria for mixed phenotype acute leukemia.
Indu M Nair, M Feroze, K P Aravindan
doaj   +1 more source

How I Approach Ethical Considerations for Pediatric Phase I CAR T‐Cell Trials

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Phase I trials of chimeric antigen receptor (CAR) T cells have shown remarkable promise in pediatric B‐cell malignancies. Such outcomes have shifted expectations for other phase I CAR T‐cell trials to have high response rates. The juxtaposition of high expectations, uncertain outcomes, and potential for life‐threatening toxicities raises ...
Sarah W. Peters, Sara K. Silbert, Elizabeth M. Holland, Annette Rid, Rayne H. Rouce, Christine Grady, Nirali N. Shah   +6 more
wiley   +1 more source

Induction of Apoptosis, G0/G1 Phase Arrest and Microtubule Disassembly in K562 Leukemia Cells by Mere15, a Novel Polypeptide from Meretrix meretrix Linnaeus

Marine Drugs, 2012
Mere15 is a novel polypeptide from Meretrix meretrix Linnaeus with cytotoxicity in solid cancer cells. In this study, we investigated its activity on human K562 chronic myelogenous leukemia cells.
Xiukun Lin, Ning Wu, Linyou Cheng, Jin Zhao, Haizhou Liu, Lin Xiao, Cuicui Wang, Xiangzhong Zhao, Ming Liu   +8 more
doaj   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Chronic myelogenous leukemia on target

Cancer Medicine, 2018
Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro‐leukemic activity of the BCR‐ABL1 oncoprotein.
Veronika Némethová, Filip Rázga
doaj   +1 more source

AS1041, a Novel Synthesized Derivative of Marine Natural Compound Aspergiolide A, Arrests Cell Cycle, Induces Apoptosis, and Inhibits ERK Activation in K562 Cells

Marine Drugs, 2017
AS1041 is a novel synthesized anthraquinone lactone derivative of marine natural compound aspergiolide A (ASP-A) with new structure skeleton and marked cytotoxicity in cancer cells.
Fengli Yuan, Liang Qiao, Yinghan Chen, Xin Qi, Yankai Liu, Dehai Li, Qianqun Gu, Jing Li, Ming Liu   +8 more
doaj   +1 more source